Premium
Clinical evaluations of a new ovarian cancer marker, COX‐1
Author(s) -
Lee G.,
Ng H.T.
Publication year - 1995
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/0020-7292(95)02406-3
Subject(s) - medicine , ovarian cancer , immunoassay , cervical cancer , monoclonal antibody , cancer , oncology , proportional hazards model , antigen , antibody , immunology
A monoclonal antibody was generated against an ovarian cancer cell line, OC‐3‐VGH and was shown to recognize a unique tumor‐associated antigen, COX‐1 found in ovarian or cervical tumors. COX‐1 can be detected in the cultured shed medium of several ovarian/cervical cancer cell lines, and in the sera of ovarian or cervical cancer patients when assayed by a sandwich immunoassay kit employing this monoclonal antibody. Multi‐medical centers clinical trials have been conducted since 1989 to evaluate the efficacy of using this immunoassay procedure for the cancer monitoring. In the case of ovarian cancer, COX‐1 immunoassay kit has the sensitivity of 68% as compared to 71% for the corresponding CA 125 kit. When both COX‐1 and CA 125 kits were combined for the simultaneous monitoring of cancer patients, the sensitivity could be increased to as high as 87%. Further analysis revealed that serum COX‐1 levels in cancer patients are correlated with stages of tumor progression. Following the surgical removal of tumors, greater than 50% of the cancer patients showed dramatic and significant decrease of serum levels of COX‐1 antigen. The results of these multi‐center clinical studies clearly suggested that COX‐1 is a suitable marker for the monitoring and diagnosis of ovarian cancer patients, when used alone or in combination with CA 125.